Gallant Closes $18 Million Series B to Bring Ready-to-Use Stem Cell Therapies for Pets to Market

~ San Diego-based animal health biotechnology company, Gallant, has successfully raised $18 million in Series B financing. The round was led by Digitalis Ventures, with continued support from BOLD Capital and Hill Creek Partners, and new participation from NovaQuest Capital Management.

Gallant is pioneering off-the-shelf stem cell therapies for pets and is creating a new category in veterinary care. Their therapies target the root cause of the most common and underserved diseases in dogs and cats. The company's first product for refractory Feline Chronic Gingivostomatitis (FCGS) is on track for FDA conditional approval in early 2026, which could make it the first FDA-labeled, allogeneic stem cell therapy in veterinary medicine.

With this funding, Gallant plans to accelerate its path to initial commercial rollout of its lead product for FCGS. They also aim to advance a pipeline of therapies for Canine and Feline Osteoarthritis (COA and FOA), Canine Atopic Dermatitis (CAD), and Feline Chronic Kidney Disease (CKD). These conditions are currently managed with treatments that only address symptoms rather than the underlying disease.

More on EntSun News

• The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
• $796,000 in Q2 Revenue Marks Highest Earnings to Date on 3 Trailing Quarters of Profitability in Multi-Billion Homebuilding Sector: Stock Symbol: IVDN
• Cybersecurity is THE Hot Market Sector; Revenues, Earnings & Profit matter; Only 33 Million Shares + a Huge Short Position Equal an Undervalued Stock
• Despite Global Calls for a Ban, US Child Psychiatry Pushes Electroshock for Kids
• Franco Polished Plaster Celebrates 35 Years of Bringing Walls to Life in the UK

Dr. Cindy Cole, Technical Partner at Digitalis Ventures, expressed her admiration for Gallant's team, vision, and ability to deliver innovative solutions to veterinarians and pets. She believes that their proprietary technology platform has the potential to bring meaningful change to animal health.

Teymour Boutros-Ghali, Managing Partner at BOLD Capital, also praised Gallant's progress in advancing a new class of therapies that are grounded in science and built for scale. He believes that their work pushes the boundaries of what is possible in veterinary care.

NovaQuest Capital Management's participation as a new investor brings valuable experience from their investment in Mesoblast. Their first product became the first-ever FDA-approved human allogeneic mesenchymal stromal cell (MSC) therapy in the U.S. in December 2024. Brian Axe, Partner at NovaQuest, stated that regenerative medicine is entering its prime and Gallant is bringing the same caliber of science to animal health.

Gallant's research has found that only 56% of veterinarians are satisfied with treatments for canine osteoarthritis and just 8% for FCGS. They also discovered that most veterinarians understand that current therapies only manage symptoms and not the underlying disease. However, roughly half of veterinarians express a strong interest in using regenerative medicine across conditions. Gallant's therapies are designed to meet this demand by being ready-to-use, science-backed, and developed under FDA oversight.

More on EntSun News

• India's Home Textile Manufacturers See Rising Demand From Us Buyers, Enabled By rivexa
• Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
• Is the Entertainment Industry in Legal Tragedy: Was Nas's song The World is Yours taken literally
• Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
• Psychologist-Turned-Hermeticist Releases Modern Guide to the Seven Hermetic Principles

Dr. Linda Black, CEO of Gallant, expressed her gratitude for having partners who share their vision of creating a new category of medicine that not only helps pets feel better but also helps them get better. She believes that the FDA approval of the first human allogeneic stem cell therapy was a historic milestone and looks forward to delivering this breakthrough therapy for animal health.

Gallant's proprietary stem cell platform utilizes uterine-derived mesenchymal stem cells to harness their unique potential. The anticipated conditional approval of their FCGS therapy would offer new hope to cats suffering from this debilitating disease and pave the way for future off-the-shelf stem cell therapies. This aligns with Gallant's larger mission of making stem cell therapy accessible to every pet in need.

---

Show All News | Report Violation